# KADOR - A French retrospective study describing the epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer.

Head: Roche Medical Data Center

Last update : 08/23/2022 | Version : 1 | ID : 74138

Last update : 08/23/2022   Version : 1   ID : 74138		
General		
Identification		
Detailed name	A French retrospective study describing the epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer.	
Sign or acronym	KADOR	
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	ML41346	
General Aspects		
Medical area	Cancer research	
Study in connection with Covid- 19	No	
Pathology (details)	Early HER2+ Breast cancer	
Health determinants	Medicine	
Keywords	Herceptin	
Scientific investigator(s) (Contact)		
Name of the director	Roche Medical Data Center	
Address	4 cours de l'Ile Seguin - 92650 BOULOGNE- BILLANCOURT	
Email	data_sharing_france@roche.com	
Organization	Roche SAS	
Collaborations		

Participati	on ir	projects,
networks	and	consortia

No

_	110	
Fun	di	na
	9	9

Funding status Private

### Governance of the database

Sponsor(s) or organisation(s) responsible

Roche SAS

Organisation status

Private

Presence of scientific or steering committees

Yes

## Additional contact

Name of the contact

https://www.roche.fr/fr/innovation-recherchemedicale/data-sharing-portail-d-informationpartage-des-donnees.html

### Main features

# Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried

out by an intermediary

A selection of health institutions and services

Database recruitment is is made

on the basis of:

Medication(s) taken

Database recruitment is carried out as part of an interventional

study

No

# Database objective

Main objective

Primary objective: To describe therapeutic management of HER2-positive early breast cancer adults' patients who have received an adjuvant treatment following Herceptin® based neoadjuvant therapy and breast surgery.

Secondary objectives:

The 2 key secondary objectives are:

1. To describe the clinical characteristics of the

patients included in the cohort, overall and per pathological response status;

2. To measure the invasive disease-free survival (IDFS) and overall survival (OS), according to pathologic response status.

# Other objectives:

- 3. To characterize adjuvant treatment failure outcomes including death, disease progression, and relapses;
- 4. To describe health care resources utilization by the targeted patients;
- 5. To estimate the number of HER2-positive early breast cancer patients who underwent breast surgery following Herceptin® based neoadjuvant treatment in France over a year (through the constitution of a registry of these patients) and number of HER2 positive early breast cancer patients with non pCR.

### Inclusion criteria

## Inclusion criteria:

- A confirmed diagnosis of HER2-positive early breast cancer;
- Initiated Herceptin® based neoadjuvant treatment during 2014 (inclusion period) followed by a breast surgery;
- A visit to any of the oncologist participating in the study during the 1-year inclusion period.

### Exclusion criteria:

-Patients with bilateral breast cancer, or participating in a clinical trial for neoadjuvant or adjuvant treatment, or already included in the registry of another participating site of the study, or who expressed disagreement on the use of their medical data will be excluded from the site's registry.

## Population type

Age

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered

Sick population

Pathology

D05 - Carcinoma in situ of breast

Gender

Woman

Geography area

**National** 

Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2014
Date of last collection (YYYY or MM/YYYY)	2018
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	301
Data	
Database activity	Data collection completed
Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Neoadjuvant treatment strategy and non-drugs treatments (surgery and radiotherapy) - Adjuvant treatment strategy and modification - Inclusion criteria variables, demographic, anthropometric, clinical and cancer characteristics - Weight, comorbidities of interest at the time of adjuvant treatment initiation - Date of last visit of the patient during the follow-up period, disease progression and reason for earlier end of observation or follow-up - Health care resources utilizations - Start and end date of patient inclusion in the registry - Date of inclusion of the first patient included and the last patient included in the registry - Number of consultations at the site during the inclusion year - Adjuvant treatment with trastuzumab (yes/No) - Type of surgery and pathologic response status.
Presence of a biobank	No
Health parameters studied	Health care consumption and services
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	eCRF

Classifications used	CDISC
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	https://www.roche.fr/fr/innovation-recherche- medicale/data-sharing-portail-d-information- partage-des-donnees.html
Presence of document that lists variables and coding procedures	Yes
	Access on specific project only
Access to aggregated data	Access on specific project only